Last reviewed · How we verify
paclitaxel, carboplatin and bevacizumab
paclitaxel, carboplatin and bevacizumab is a Small molecule drug developed by Spanish Lung Cancer Group. It is currently in Phase 2 development. Also known as: Taxol, carboplatin, avastin.
At a glance
| Generic name | paclitaxel, carboplatin and bevacizumab |
|---|---|
| Also known as | Taxol, carboplatin, avastin |
| Sponsor | Spanish Lung Cancer Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paclitaxel, carboplatin and bevacizumab CI brief — competitive landscape report
- paclitaxel, carboplatin and bevacizumab updates RSS · CI watch RSS
- Spanish Lung Cancer Group portfolio CI
Frequently asked questions about paclitaxel, carboplatin and bevacizumab
What is paclitaxel, carboplatin and bevacizumab?
paclitaxel, carboplatin and bevacizumab is a Small molecule drug developed by Spanish Lung Cancer Group.
Who makes paclitaxel, carboplatin and bevacizumab?
paclitaxel, carboplatin and bevacizumab is developed by Spanish Lung Cancer Group (see full Spanish Lung Cancer Group pipeline at /company/spanish-lung-cancer-group).
Is paclitaxel, carboplatin and bevacizumab also known as anything else?
paclitaxel, carboplatin and bevacizumab is also known as Taxol, carboplatin, avastin.
What development phase is paclitaxel, carboplatin and bevacizumab in?
paclitaxel, carboplatin and bevacizumab is in Phase 2.
Related
- Manufacturer: Spanish Lung Cancer Group — full pipeline
- Also known as: Taxol, carboplatin, avastin
- Compare: paclitaxel, carboplatin and bevacizumab vs similar drugs
- Pricing: paclitaxel, carboplatin and bevacizumab cost, discount & access